Bial--R&D Investments, S.A.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Bial--R&D Investments, S.A..The latest application filed is for "substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders".

Company Profile

0.13.3

Bial--R&D Investments, S.A. - Coronado N/A PT
Bial - R&D Investments, S.A. - Coronado (S.Romao e S.Mamede) PT

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders Grant 11,453,675 - Skerlj , et al. September 27, 2	2022-09-27
Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders Grant 11,400,095 - Skerlj , et al. August 2, 2	2022-08-02
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS App 20220185814 - Skerlj; Renato T. ; et al.	2022-06-16
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders Grant 11,351,173 - Skerlj , et al. June 7, 2	2022-06-07
Substituted Pyrazolo[1,5-a]pyrimidines And Their Use In The Treatment Of Medical Disorders App 20220169652 - Skerlj; Renato T. ; et al.	2022-06-02
Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders Grant 11,345,698 - Skerlj , et al. May 31, 2	2022-05-31
Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders Grant 11,192,892 - Skerlj , et al. December 7, 2	2021-12-07
Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders Grant 11,168,087 - Skerlj , et al. November 9, 2	2021-11-09
Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders Grant 11,091,492 - Skerlj , et al. August 17, 2	2021-08-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.